Companies › GI Innovation
4 active drug programs in 7 registered trials: 5 Phase 1, 2 Phase 2; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GI-102 CD80-IgG4 Fc-IL2v3 fusion protein | CD80 | Phase 2 | Cancer Survivors; Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer (mCRPC) | Apr 2027 |
| GI-108 Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein | CD73, IL2RA | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| GI-101 | – | Phase 1 | Advanced Solid Tumor | Jun 2028 |
| GI-101A | – | Phase 1 | Advanced Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07363057 | GI-102 | Phase 2 | Cancer Survivors | Oncology | May 2026 |
| NCT07363057 | GI-102 | Phase 2 | Cancer Survivors | Oncology | May 2026 |
| NCT07172802 | GI-108 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT05824975 | GI-102 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT04977453 | GI-101 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2028 |
| NCT04977453 | GI-101A | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2028 |
| NCT07871435 | GI-102 | Phase 1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | Mar 2029 |
Bristol-Myers Squibb Coya Therapeutics AP Biosciences Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG Synthekine AgonOx CellTrans
Kumquat Biosciences Vividion Therapeutics Eikon Therapeutics Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) RayzeBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.